PONV Clinical Trial
Official title:
Randomized, Double-blind, Placebo-controlled Phase III Study of Amisulpride for IV Injection as Prophylaxis Against Post-operative Nausea and Vomiting
A comparison of the efficacy of Amisulpride and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.
Status | Not yet recruiting |
Enrollment | 516 |
Est. completion date | December 31, 2023 |
Est. primary completion date | August 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: Inclusion Criteria: 1. Participant understand the study procedures and methods, voluntarily participate in this trial, and sign the informed consent. 2. Male or female patients = 18 years of age and =75 years of age. 3. 18<BMI=30kg/m^2,And weigh more than 45kg 4. Patients undergoing elective surgery(laparoscopic gynecological or abdominal surgery) under general anaesthesia requiring,and inhalation anesthesia is maintained for more than 1 hour, but patients who receive purely diagnostic surgery cannot be enrolled; 5. Patients with at least 2 of the following risk factors for PONV: Past history of PONV and/or motion sickness Habitual non-smoking status Female sex Expected to receive opioid analgesia post-operatively 6. American Society of Anesthesiologists (ASA) risk score I-III - Exclusion Criteria: 1. Patients undergoing day case surgery 2. Patients undergoing intra-thoracic, transplant or central nervous system surgery or any surgery where post-operative emesis may pose a significant danger to the patient 3. Patients planned to receive only a local anaesthetic and/or regional neuraxial (intrathecal or epidural) block 4. Patients who are scheduled to be transferred to the ICU after surgery; 5. Patients who are expected to need a naso- or oral-gastric tube in situ after surgery is completed 6. Patients who have a documented, clinically significant cardiac arrhythmia or congenital long QT syndrome(Male= 450 ms female= 460ms). 7. Adequate hepatic and renal function, Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) = 2.5 x upper limit normal (ULN),Bilirubin = 1.5 x ULN,Creatinine = 1.5x ULN 8. Patients who have received Amisulpride active ingredient for any indication within the last 2 weeks 9. Patients who are allergic to Amisulpride active ingredient or any of the excipients of Amisulpride 10. Patients with a significant, ongoing history of vestibular disease or dizziness 11. Intestinal obstruction 12. Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or breast cancer) or phaeochromocytoma. 13. Patients with pre-existing nausea or vomiting in the 24 hours before surgery 14. Patients treated with regular anti-emetic therapy including corticosteroids 15. Patients being treated with medications which could induce torsades de pointes, including Class Ia antiarrhythmic agents such as quinidine, disopyramide, procainamide; Class III antiarrhythmic agents such as amiodarone and sotalol; and other medications such as bepridil, cisapride, thioridazine, methadone, IV erythromycin, IV vincamine, halofantrine, pentamidine, sparfloxacin 16. Patients being treated with levodopa or other dopamine drugs 17. Patients who are pregnant or breast feeding. 18. Participant who has a history of drug or alcohol abuse within 6 months before randomization 19. Patients diagnosed with Parkinson's disease ,Patients with a history of epilepsy. 20. Patients who have received anti-cancer chemotherapy in the previous 4 weeks of surgery 21. Patients who have participated in other clinical research trials within 3 months before randomization 22. Participant who may increase study-related risks or interfere with the interpretation of study results in the opinion of the investigator, who are considered unsuitable for enrollment by the investigator and/or the sponsor. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Qilu Pharmaceutical (Hainan) Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint was the composite measure complete response | defined as no episodes of emesis (vomiting or retching) and no use of rescue medication in the first 24h after wound closure | 24 hours after the end of surgery | |
Secondary | Incidence of no Nausea | Count of patients experiencing an episode of no nausea scored < 1 of 0-10 verbal response scale during the 24 hours period after the completion of surgery | 24 hours after end of surgery | |
Secondary | Incidence of moderate and severe Nausea | Count of participants with nausea score > 4 on 0-10 verbal response scale | 24 hours after end of surgery | |
Secondary | Incidence of Emesis (Vomiting/Retching) | An assessment of a participant experiencing an episode of emesis (vomiting/ retching) during the 24hours after the completion of the surgery | 24 hours after end of surgery | |
Secondary | Use of Rescue Medication | 24 hours after end of surgery | ||
Secondary | Time to First Violation of Criteria for PONV | Criteria for PONV are any episode of emesis or use of rescue medication in the 24 hours after the end of surgery | 24 hours after end of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01945502 -
Nasopharyngeal Packing and Rhinologic Surgery.
|
N/A | |
Completed |
NCT01840254 -
Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial
|
N/A | |
Completed |
NCT00760253 -
Compare the Side Effects and Difference Awake Level of Three TCI Propofol Formula in TVOR Patients
|
N/A | |
Completed |
NCT00772226 -
The Use of Music as Pain Therapy in Patients Undergoing Laparoscopic Cholecystectomy in a Day Care Unit
|
Phase 3 | |
Recruiting |
NCT03783182 -
Betamethasone (Betapred®) as Premedication for Reducing Postoperative Vomiting and Pain After Tonsillectomy
|
Phase 4 | |
Recruiting |
NCT03835234 -
Incidence and Factors Associated With PONV in Regional Anaesthesia
|
||
Recruiting |
NCT04191694 -
Chewing Gum to Prevent Nausea and Vomiting After Caesarean Section Under Spinal Anaesthesia
|
N/A | |
Completed |
NCT02468323 -
Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia
|
Phase 4 | |
Recruiting |
NCT05596695 -
Minimisation of Blood Pressure Variability and Postoperative Nausea and Vomiting
|
N/A | |
Recruiting |
NCT04570592 -
Granisetron vs Granisetron and Dexamethasone on the Reduction of Postoperative Nausea and Vomiting
|
Phase 2 | |
Completed |
NCT02116257 -
The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV
|
N/A | |
Not yet recruiting |
NCT05396716 -
Acupoint Stimulation Alleviates Postoperative Nausea and Vomiting
|
N/A | |
Active, not recruiting |
NCT00892996 -
Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section
|
N/A | |
Recruiting |
NCT04866121 -
Acupuncture for Prevention of Postoperative Nausea and Vomiting
|
N/A | |
Completed |
NCT02809378 -
The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV
|
Phase 4 | |
Completed |
NCT05408676 -
Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery
|
N/A | |
Completed |
NCT01991821 -
European Phase III Study of APD421 in PONV
|
Phase 3 | |
Completed |
NCT00952133 -
Efficacy of IV Palo With IV Dexamethasone vs IV Palo for Prevention of Immediate & Delayed PONV
|
Phase 4 | |
Completed |
NCT04054479 -
Penehyclidine for PONV Prophylaxis After Strabismus Surgery
|
Phase 4 | |
Completed |
NCT05540236 -
Effects of Auricular Acupressure on the Management of Postoperative Nausea and Vomiting After Gynecological Laparoscopic Surgeries
|
N/A |